List of Excipients in Branded Drug PEPCID AC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Kenvue Brands LLC	PEPCID AC	famotidine	16837-855	CARNAUBA WAX
Kenvue Brands LLC	PEPCID AC	famotidine	16837-855	CELLULOSE, MICROCRYSTALLINE
Kenvue Brands LLC	PEPCID AC	famotidine	16837-855	HYDROXYPROPYL CELLULOSE

PEPCID AC Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: August 7, 2026

PEPCID AC is an over-the-counter famotidine product family marketed primarily for heartburn relief. Its commercial opportunity is concentrated in differentiated dosage forms, taste masking, rapid disintegration, combination antacid products, preservative-free liquid systems, and private-label manufacturing. The active ingredient is generic and faces limited molecule-level exclusivity. Competitive advantage therefore depends on formulation performance, brand recognition, regulatory execution, packaging, and retail distribution.

The analysis below focuses on U.S. PEPCID AC products, including famotidine tablets, chewables, and combination products. Excipients vary by strength, dosage form, flavor, manufacturer, and market.

What is PEPCID AC and how is it regulated?

PEPCID AC contains famotidine, an H2-receptor antagonist that reduces gastric acid secretion. U.S. products are sold without a prescription for the relief and prevention of heartburn associated with acid indigestion.

The product family includes:

Product type	Active ingredients	Typical commercial positioning
PEPCID AC Original Strength	Famotidine 10 mg	Occasional heartburn relief
PEPCID AC Maximum Strength	Famotidine 20 mg	Stronger single-dose relief
PEPCID AC Chewables	Famotidine, commonly 10 mg or 20 mg	No-water administration
PEPCID Complete	Famotidine plus calcium carbonate and magnesium hydroxide	Faster antacid relief plus longer acid suppression
Store-brand equivalents	Famotidine, with or without antacids	Price-driven substitution

Famotidine products may be marketed under the FDA’s OTC H2-blocker regulatory framework or through approved drug applications, depending on the product and historical regulatory pathway. Product-specific labeling, inactive ingredients, dosage forms, and manufacturing sites must be checked against the current FDA Drugs@FDA record and DailyMed entry.

PEPCID AC is a small-molecule OTC drug. Biosimilar regulation does not apply. Generic competition, private-label substitution, and authorized or equivalent OTC products are the primary market risks.

What excipients are used in PEPCID AC formulations?

PEPCID AC excipients are formulation-specific. Common excipient classes include fillers, binders, disintegrants, lubricants, coating agents, sweeteners, flavors, colors, and pH-control materials.

Immediate-release tablets

Immediate-release famotidine tablets typically require:

• A filler or diluent to provide tablet mass.
• A binder to support mechanical strength.
• A superdisintegrant to promote rapid breakup after ingestion.
• A lubricant to control ejection and prevent sticking.
• A film coating for appearance, swallowability, moisture protection, and product identification.
• Colorants and opacifiers where required for brand presentation.

Common excipient candidates for equivalent or improved formulations include microcrystalline cellulose, lactose, starch, croscarmellose sodium, sodium starch glycolate, crospovidone, colloidal silicon dioxide, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide, and iron oxides. The specific inactive ingredients in a marketed product should not be inferred solely from the dosage form because excipient selection can change between strengths and manufacturing sites.

Famotidine has a relatively low dose compared with the total tablet mass. That creates flexibility for direct-compression systems, but the formulation must control content uniformity, tablet hardness, disintegration time, friability, and dissolution.

Chewable tablets

Chewable PEPCID AC products have a different excipient strategy. The formulation must balance:

1. Mechanical strength during packaging and transport.
2. Rapid mastication and oral dispersion.
3. Acceptable mouthfeel.
4. Sweetness and flavor persistence.
5. Low grittiness and low chalkiness.
6. Stability under humidity exposure.

Chewable systems may use mannitol, sorbitol, compressible sugars, microcrystalline cellulose, crospovidone, flavor systems, high-intensity sweeteners, and lubricants. Polyols can improve cooling sensation and mouthfeel but may create hygroscopicity and tablet-softening risks. Calcium carbonate-containing products add an inorganic load that can increase chalkiness and alter tablet density.

Taste masking is commercially important because famotidine can produce an undesirable medicinal taste. Options include polymeric coating of drug particles, ion-exchange resins, lipid barriers, cyclodextrin complexes, and multiparticulate granules. A taste-masking system may support a defensible formulation patent if it produces a measurable improvement in dissolution, palatability, stability, or dose uniformity.

Combination products

PEPCID Complete combines famotidine with antacid actives, typically calcium carbonate and magnesium hydroxide. The excipient strategy must accommodate two distinct release objectives:

• Immediate neutralization from the antacid components.
• Longer-duration acid suppression from famotidine.

Potential formulation conflicts include:

• Chemical or physical interaction between famotidine and alkaline antacid materials.
• Altered dissolution caused by high mineral content.
• Inconsistent suspension or dispersion if the product is converted into a liquid.
• Increased tablet weight and friability.
• Taste and mouthfeel problems.
• Assay and content-uniformity challenges across multiple active ingredients.

Combination products create more technical differentiation than single-ingredient famotidine tablets. They also impose greater regulatory and manufacturing complexity.

What commercial opportunities exist for PEPCID AC excipients?

The strongest opportunities are not in commodity fillers. They are in excipient systems that improve a consumer-relevant attribute and can be supported by data.

1. Rapid-dissolution famotidine tablets

A rapid-dissolution platform could target faster onset of drug release without changing the labeled dose. Relevant technologies include:

• Co-processed excipients for direct compression.
• High-efficiency superdisintegrants.
• Porous granules.
• Effervescent or partially effervescent systems.
• Low-moisture granulation.
• Wetting agents that improve tablet penetration.

The commercial claim must remain within the permitted OTC labeling framework. A formulation can be differentiated through manufacturing, packaging, or consumer communication, but an unsupported claim of faster clinical relief creates regulatory risk.

2. Superior-tasting chewables

Taste-masked chewables are attractive because consumers often choose heartburn products based on convenience and sensory acceptance. Opportunity areas include:

• Lower aftertaste.
• Reduced chalkiness in antacid combinations.
• Sugar-free systems with improved cooling and reduced grittiness.
• Flavor systems that remain stable throughout shelf life.
• Smaller tablets with equivalent dose delivery.
• Orally disintegrating formats that do not require chewing.

The best commercial candidates would demonstrate comparative sensory performance, dissolution equivalence, tablet robustness, and stability under accelerated humidity conditions.

3. Sugar-free and low-calorie dosage forms

Sugar-free products can appeal to consumers managing calorie intake, diabetes, or dental concerns. Suitable excipient systems may use mannitol, xylitol, sorbitol, sucralose, acesulfame potassium, or steviol glycosides.

The main development risks are hygroscopicity, polyol-related gastrointestinal effects, flavor instability, and elevated manufacturing cost. A low-sugar positioning alone may not justify a premium unless the product also improves taste, portability, or dosing convenience.

4. Liquid and pediatric-friendly products

Famotidine liquids could address consumers who cannot swallow tablets. Commercial development would require control of:

• Suspension uniformity.
• Sedimentation and redispersibility.
• Palatability.
• Preservative effectiveness.
• pH stability.
• Container compatibility.
• Dose measurement accuracy.

A liquid product would face a larger microbial-control burden than a dry tablet. Single-dose sachets, unit-dose cups, or ready-to-use suspensions may reduce dosing errors but increase packaging cost.

5. Moisture-resistant packaging and excipient systems

Fomulation and packaging should be developed together. Chewable and rapidly disintegrating products are sensitive to humidity. Commercial options include:

• High-barrier blister packaging.
• Desiccant-integrated bottles.
• Unit-dose foil sachets.
• Moisture-resistant coatings.
• Low-water-activity excipient systems.
• Nitrogen-flushed packaging where justified.

Packaging patents and manufacturing know-how can protect a product even when the excipient list is readily discoverable.

What formulation patents may protect PEPCID AC products?

Patent protection for a famotidine OTC product is more likely to attach to the formulation, dosage form, manufacturing process, packaging system, or combination than to famotidine itself.

Potential claim categories include:

Claim category	Protected subject matter	Commercial value
Taste masking	Coated particles, resin complexes, flavor systems	High for chewables and orally disintegrating products
Rapid release	Disintegrant systems, porous tablets, wetting systems	Moderate to high
Combination formulation	Famotidine with calcium carbonate and magnesium hydroxide	High if stability and release are difficult to reproduce
Low-moisture systems	Excipient selection and water-activity control	Moderate
Liquid suspension	Suspending agents, preservatives, redispersibility	Moderate
Manufacturing process	Granulation, coating, compression, blending	High if difficult to design around
Packaging	Blister, desiccant, unit-dose, moisture barrier	Moderate
Method of use	Dosing regimen or prevention of heartburn	Limited for OTC products unless clinically differentiated

A patent covering a specific inactive-ingredient combination may be vulnerable if competitors can substitute functionally equivalent excipients. Stronger protection usually requires a narrow technical relationship, such as a defined particle coating, dissolution profile, stability threshold, or manufacturing sequence.

Patent term depends on the actual U.S. filing date, patent-term adjustments, terminal disclaimers, and any patent-term extension. Current patent status must be confirmed in USPTO Patent Center and Google Patents. No reliable conclusion about active PEPCID AC formulation patents should be drawn from the brand name alone.

What is the Orange Book status of PEPCID AC?

The Orange Book primarily identifies approved prescription and certain approved nonprescription drug products. OTC monograph products and legacy OTC products may not have the same Orange Book listing structure as prescription NDA products.

For PEPCID AC, the relevant diligence questions are:

• Whether the specific product is approved under an NDA or marketed under an OTC monograph.
• Whether the product has an active NDA listing.
• Whether patents are listed for the specific drug product.
• Whether an applicant can submit an ANDA or must use the OTC monograph pathway.
• Whether the proposed generic or private-label product is therapeutically equivalent to the reference product.

A generic famotidine tablet does not automatically substitute for a combination product containing famotidine, calcium carbonate, and magnesium hydroxide. The dosage form, active ingredients, strengths, labeling, and regulatory pathway must match the relevant reference or monograph requirements.

When does PEPCID AC lose exclusivity?

PEPCID AC has already lost practical molecule-level exclusivity. Famotidine is widely available from generic manufacturers and store brands.

The remaining commercial protections are brand-level and product-specific:

• Trademark protection for PEPCID and related marks.
• Retail shelf position.
• Consumer recognition.
• Formulation patents, if any remain enforceable.
• Trade secrets involving flavor, processing, coating, or scale-up.
• Packaging and merchandising.
• Regulatory investment in combination products.
• Distribution relationships.

The absence of molecule exclusivity does not eliminate commercial barriers. A branded OTC product can retain pricing power if it delivers stronger consumer trust, superior taste, faster perceived relief, or better retail visibility.

Which companies are challenging PEPCID AC commercially?

The main competitors are generic and private-label famotidine suppliers, other H2 blockers, and antacid brands.

Competitive group	Examples	Competitive mechanism
Generic famotidine	Multiple authorized generic and private-label suppliers	Lower price and broad retail availability
Other H2 blockers	Cimetidine products where available	Alternative H2-blocker therapy
Proton-pump inhibitors	Omeprazole, lansoprazole, esomeprazole OTC products	Longer-duration acid suppression
Antacids	Calcium carbonate, magnesium hydroxide, aluminum hydroxide products	Rapid neutralization
Combination products	Famotidine-antacid products	Combined rapid and sustained relief
Retailer brands	Store-brand heartburn products	Price substitution

Generic manufacturers do not need to challenge PEPCID AC through Paragraph IV litigation if the relevant product is marketed under an OTC monograph or if no listed patent blocks entry. Paragraph IV exposure depends on the regulatory pathway and the existence of Orange Book-listed patents for the reference product.

What Paragraph IV and litigation risks affect PEPCID AC?

Paragraph IV risk is product-specific. A competitor may use a Paragraph IV certification against listed patents associated with an NDA product, but a standard OTC monograph product may not create the same filing structure.

The principal litigation risks are:

• Patent infringement claims involving formulation or combination patents.
• Trade dress and trademark disputes.
• False advertising claims concerning onset, duration, or comparative efficacy.
• Challenges involving inactive ingredients and allergen labeling.
• Product liability claims related to dosing or contamination.
• Manufacturing and quality disputes involving dissolution or content uniformity.

No broad conclusion that PEPCID AC is currently subject to active Paragraph IV litigation or a settlement agreement should be made without a current review of PACER, FDA Orange Book records, and USPTO records. Litigation involving prescription famotidine products would not necessarily affect OTC PEPCID AC.

How strong is the PEPCID AC patent estate?

The likely strength of the PEPCID AC patent estate is moderate at the brand level and weaker at the active-ingredient level.

Stronger protection

Protection is stronger when the product depends on:

• A combination of multiple active ingredients.
• A specific taste-masking architecture.
• A narrow dissolution or disintegration profile.
• A difficult-to-reproduce coating process.
• A validated moisture-control system.
• A specialized manufacturing sequence.
• A product-specific clinical or consumer benefit.

Weaker protection

Protection is weaker when claims cover:

• Conventional tablet excipients.
• Broad ranges of common fillers or lubricants.
• Generic chewable-tablet structures.
• Standard antacid mixtures.
• Routine flavor and color combinations.
• Easily substituted excipient classes.

The strongest competitive moat may therefore be operational rather than legal. Scale, quality consistency, retail placement, and consumer marketing can be more important than a narrow formulation patent.

How does PEPCID AC compare with generic famotidine?

Factor	PEPCID AC	Generic famotidine
Active ingredient	Famotidine	Famotidine
Molecule exclusivity	None of practical significance	None
Pricing	Usually premium	Usually lower
Consumer recognition	High	Variable
Formulation differentiation	Stronger in branded chewables and combinations	Often standard tablets
Retail distribution	Broad branded placement	Broad but price-dependent
Patent value	Potentially formulation- or combination-specific	Usually limited
Switching risk	High where products are therapeutically interchangeable	High
Margin support	Brand, convenience, and formulation	Scale and low cost

A generic manufacturer can compete effectively with a conventional famotidine tablet. It has a harder task reproducing a branded sensory profile, combination-product performance, packaging configuration, or consumer-perceived onset without infringing valid claims or duplicating trade secrets.

What manufacturing and IP barriers matter most?

The main manufacturing barriers are process consistency and sensory quality, not raw-material scarcity.

Critical controls include:

• Uniform famotidine distribution at low dose.
• Powder-flow behavior.
• Compression-force control.
• Tablet friability.
• Dissolution and disintegration.
• Coating uniformity.
• Flavor retention.
• Moisture uptake.
• Antacid particle-size distribution.
• Blend segregation.
• Stability through shelf life.

Excipient suppliers can capture value by offering co-processed excipients, taste-masking platforms, high-barrier packaging, and technical support for scale-up. The most defensible supplier position combines proprietary processing with regulatory documentation and demonstrated performance in a finished PEPCID AC-like dosage form.

What licensing opportunities exist for PEPCID AC excipients?

Potential licensing targets include:

1. Taste-masked famotidine particles for chewable products.
2. Co-processed direct-compression excipients for rapid disintegration.
3. Sugar-free flavor and sweetener systems.
4. Low-moisture antacid-famotidine combinations.
5. Ready-to-use liquid suspension platforms.
6. Unit-dose packaging with moisture control.
7. Manufacturing processes that improve content uniformity or reduce coating cost.

A licensing transaction would be more attractive if the technology provides one or more measurable advantages:

• Lower cost per dose.
• Faster production.
• Reduced manufacturing rejects.
• Better stability.
• Improved consumer sensory scores.
• Easier regulatory justification.
• Patent claims that cover the commercial embodiment.
• Compatibility with multiple brands and private-label customers.

Broad excipient patents are difficult to monetize when equivalent materials are readily available. Platform technologies that apply to H2 blockers, antacids, analgesics, and other OTC categories offer a larger addressable market.

What generic launch scenarios exist for PEPCID AC?

Scenario 1: Standard tablet substitution

This is the lowest-barrier scenario. A manufacturer launches a generic famotidine tablet under an OTC monograph or applicable approval pathway. Price competition increases, but the branded product retains value through recognition and merchandising.

Scenario 2: Chewable competition

A generic or private-label company launches a chewable famotidine product. The main barriers are taste, texture, stability, and consumer acceptance. A similar label claim does not ensure equivalent sensory performance.

Scenario 3: Combination-product entry

A competitor launches a famotidine-antacid combination. This scenario creates greater formulation and regulatory complexity. Antacid ratios, active compatibility, dissolution, labeling, and tablet size become important entry barriers.

Scenario 4: Premium convenience product

A competitor targets orally disintegrating, unit-dose, liquid, or highly portable formats. This product may avoid direct price competition if it creates a distinct consumer-use occasion, but the formulation must justify the premium.

What is the revenue exposure from excipient-driven competition?

Revenue exposure is highest in products where the active ingredient is commoditized and the brand premium depends on consumer experience.

The most exposed segments are:

• Standard 10 mg and 20 mg tablets.
• Large bottle formats.
• Products with no distinctive sensory or packaging benefit.
• Retail channels with aggressive private-label pricing.
• High-volume seasonal heartburn categories.

Exposure is lower for:

• PEPCID Complete-type combinations.
• Strongly differentiated chewables.
• Products with superior taste or convenience.
• Travel and unit-dose packages.
• Clinically or consumer-validated rapid-relief formats.

A practical diligence model should separate revenue into four pools: branded single-ingredient products, branded combination products, chewables, and licensing or private-label opportunities. The first pool is most vulnerable to generic substitution. The combination and convenience pools have greater potential for excipient-driven differentiation.

Key Takeaways

• PEPCID AC is an OTC famotidine brand with no meaningful molecule-level exclusivity.
• The principal commercial moat is formulation execution, brand equity, packaging, and retail distribution.
• Excipients create the most value in chewables, rapid-dissolution products, combination antacid systems, liquids, and sugar-free products.
• Taste masking, moisture control, dissolution, and mouthfeel are the most commercially relevant technical targets.
• Combination products have stronger formulation differentiation but higher regulatory and manufacturing complexity.
• Paragraph IV exposure and Orange Book status must be evaluated at the specific product and NDA level.
• Biosimilar risk does not apply. Generic and private-label substitution are the central competitive threats.
• Excipient licensing is most attractive when the technology reduces cost, improves sensory performance, strengthens stability, or supports a defensible patent position.
• Standard famotidine tablets are highly vulnerable to price competition. Combination and convenience formats offer better opportunities for margin protection.

FAQs

Can a new excipient create exclusivity for a PEPCID AC equivalent?

A new excipient can support formulation patent claims, but it does not automatically create regulatory exclusivity. The formulation must satisfy applicable FDA requirements, and the patent must cover a commercially relevant, non-obvious implementation.

Which PEPCID AC format offers the strongest excipient opportunity?

Chewable and combination products generally offer more opportunity than conventional tablets because taste, texture, active compatibility, and release performance create more technical variables.

Are famotidine excipients interchangeable between manufacturers?

No. Substitution can change dissolution, compression, stability, taste, tablet strength, and labeling. Functional equivalence requires product-specific development and testing.

Can a private-label manufacturer copy PEPCID AC excipients?

Public inactive-ingredient disclosures can assist development, but copying the exact formulation or process may create patent, trade-secret, trademark, or regulatory risks. Functional substitution is usually more practical.

Does PEPCID Complete have greater patent value than standard PEPCID AC?

Potentially. A multi-active formulation can create more complex compatibility and release requirements. Its patent strength still depends on the scope, validity, expiration, and enforceability of the specific claims.

References

1. U.S. Food and Drug Administration. (n.d.). DailyMed: PEPCID AC and famotidine product labeling. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
4. U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs
5. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 331: Antacid products for over-the-counter human use. https://www.ecfr.gov/
6. United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
7. Kenvue Inc. (n.d.). PEPCID product information. https://www.pepcid.com/